A simple blood test can now identify who carries the genetic risk before symptoms appear.
Out of Brazil's Federal University of Rio Grande do Sul, a team of researchers has illuminated one of the quieter inheritances carried by more than a quarter of humanity: a genetic variant that tilts the brain, over time, toward forgetting. By tracing how the Apoe4 gene accelerates the accumulation of tau and amyloid proteins at the molecular level, the scientists have not only deepened our understanding of Alzheimer's origins but opened a door toward medicine that meets each patient where their biology begins. As the disease approaches a projected toll of 100 million lives by 2030, the discovery arrives as both a warning and a compass.
- More than a quarter of the global population unknowingly carries a gene variant that multiplies their Alzheimer's risk by up to 15 times, making this one of the most consequential genetic findings in recent dementia research.
- The Apoe4 variant triggers a chemical distortion of tau protein and accelerates amyloid plaque buildup simultaneously, creating a dual assault on the brain that drives neurological decline faster than previously understood.
- A simple blood test can now detect Apoe4 carriers before any symptoms emerge, offering a narrow but critical window for early intervention in a disease that has long resisted prevention.
- Two newly approved drugs — lecanemab and donanemab — target the amyloid pathway this gene exploits, but neither is yet available in Brazil, where patients remain limited to medications that manage symptoms rather than slow the disease.
- The research team envisions combining genetic screening with these therapies to predict individual drug response, moving Alzheimer's treatment toward a personalized model at a moment when the global caseload is accelerating rapidly.
Researchers at Brazil's Federal University of Rio Grande do Sul have mapped the precise molecular pathway through which a common genetic variant drives the brain toward Alzheimer's disease. Published in Nature Aging, the study traces how the Apoe4 gene variant accelerates both the hyperphosphorylation of tau protein — disrupting the structural scaffolding of neurons and causing cell death — and the accumulation of amyloid plaques. Together, these two processes constitute the core neurological damage of Alzheimer's.
The scale of the finding is sobering. Roughly 25 percent of the global population carries one copy of Apoe4, and about 1 percent carries two. Those with a single copy face three to four times the normal risk of developing Alzheimer's; those with two copies face 12 to 15 times the risk. This is distinct from the inherited familial forms of the disease, which account for only about 10 percent of cases.
The study was led by doctoral student João Pedro Ferrari Souza, working under advisors at UFRGS and the University of Pittsburgh, with collaborators from McGill University and the University of Gothenburg. Over two years, the team analyzed 94 Alzheimer's patients using cerebrospinal fluid tests, blood work, MRI imaging, and PET scans.
The discovery carries immediate practical weight. Blood tests can now identify Apoe4 carriers before symptoms appear, and two recently approved drugs — donanemab and lecanemab — target the amyloid accumulation this variant accelerates. Souza envisions using genetic screening to predict which patients will respond best to these therapies. Neither drug is yet available in Brazil, however, where current treatments only manage symptoms. With Alzheimer's projected to affect more than 100 million people worldwide by 2030, the team's work points toward a more targeted, personalized era of treatment — one built on knowing a patient's genetic profile before the disease takes hold.
Researchers at Brazil's Federal University of Rio Grande do Sul have mapped out the precise way a common genetic variant pushes the brain toward Alzheimer's disease. The work, published in Nature Aging in late September, traces how copies of a gene called Apoe—specifically its epsilon-4 variant—accelerates the buildup of two proteins, amyloid-beta and tau, that are hallmarks of cognitive decline.
The mechanism works through a process called hyperphosphorylation. Normally, tau protein maintains the structure of neurons. But when the Apoe4 variant is present, tau becomes chemically altered in a way that breaks down this maintenance function, leading to cell death. At the same time, the variant speeds up the accumulation of amyloid plaques in the brain. Together, these two processes drive the neurological damage that defines Alzheimer's.
The scale of the finding is striking. About 25 percent of the global population carries one copy of the Apoe4 gene, and roughly 1 percent carries two copies. That means more than a quarter of humanity has a significantly elevated genetic risk for dementia. Those with one copy face three to four times the normal risk of developing Alzheimer's; those with two copies face 12 to 15 times the risk. It's important to note that this genetic predisposition is distinct from the inherited forms of Alzheimer's that run in families—those account for about 10 percent of cases.
The research was led by João Pedro Ferrari Souza, a doctoral student in biochemistry at the university who spent a year in the United States as part of his training, working under Eduardo Zimmer at UFRGS and Tharick Pascoal at the University of Pittsburgh. Collaborators from McGill University in Canada and the University of Gothenburg in Sweden also contributed. Over two years, the team studied 94 Alzheimer's patients from McGill's Triad study, subjecting them to four types of analysis: cerebrospinal fluid testing, blood work, MRI imaging, and PET scans designed to detect amyloid plaques.
The practical value of this discovery lies in early detection and treatment planning. A simple blood test can now identify who carries the Apoe4 variant before symptoms appear. This matters because two new drugs—donanemab from Eli Lilly and lecanemab from Biogen—have recently been approved to slow cognitive decline in early-stage Alzheimer's by targeting amyloid accumulation. Souza envisions combining genetic screening with these new treatments: identify the gene variant, then use that information to predict how well a particular patient will respond to the drugs.
Neither medication is yet available in Brazil. Eli Lilly has not submitted donanemab for regulatory approval to Brazil's health authority, and as of mid-2023, there was no timeline for lecanemab's arrival. The drugs currently available in Brazil for Alzheimer's treatment—donepezil, galantamine, rivastigmine, and memantine—only manage symptoms rather than slow the disease's progression. The new drugs do carry risks: clinical trials documented rare but serious side effects including brain swelling and cerebral bleeding.
Still, Souza is optimistic that the team's work will accelerate development of new therapies and refine how existing ones are deployed. The stakes are enormous. Alzheimer's is projected to affect more than 100 million people worldwide by 2030. Understanding how genetic risk factors like Apoe4 drive the disease at the molecular level opens a path toward more targeted, personalized approaches—moving beyond one-size-fits-all treatment toward interventions tailored to each patient's genetic profile.
Citas Notables
The Apoe4 variant accelerates the effect that amyloid has on tau protein accumulation, with one copy conferring 3-4x greater risk and two copies conferring 12-15x greater risk compared to non-carriers.— João Pedro Ferrari Souza, doctoral researcher at UFRGS
These findings help us understand this important neurodegenerative condition that is projected to affect more than 100 million people worldwide by 2030, with direct implications for Alzheimer's treatment.— João Pedro Ferrari Souza
La Conversación del Hearth Otra perspectiva de la historia
So this gene variant—Apoe4—it's not rare. You're saying a quarter of people have it?
Exactly. One copy in about 25 percent of the population, two copies in about 1 percent. It's not some exotic mutation. It's common enough that this affects hundreds of millions of people.
But having the gene doesn't mean you'll get Alzheimer's, right?
Right. It increases your risk substantially—three to fifteen times depending on whether you have one or two copies—but it's not a guarantee. It's a vulnerability, not a sentence.
What changed with this research? Why does it matter now?
They figured out the exact mechanism. How the gene makes tau protein malfunction, how it speeds up amyloid buildup. And crucially, they showed you can detect it with a blood test before symptoms show up.
So you could know your risk years in advance?
Yes. And now that matters because there are new drugs that actually slow the disease if you catch it early. Before, knowing your risk didn't change much. Now it could guide treatment.
Are these drugs available to people?
Not in Brazil yet. They're approved in other countries, but they're not here. And they do have serious side effects—brain swelling, bleeding. They're not simple solutions.
So what's the real significance of this discovery?
It's a map. It shows how the disease works at the molecular level, and it gives doctors a way to identify high-risk people and potentially personalize treatment. In a disease that's going to affect over 100 million people by 2030, that's significant.